Current methods for investigation of receptor - ligand interactions in drug discovery are based on three-dimensional complementarity of receptor and ligand surfaces, and they include pharmacophore modelling, QSAR, molecular docking etc. Those methods only consider short-range molecular interactions (distances <5A), and not include long-range interactions (distances >5A) which are essential for kinetic of biochemical reactions because they influence the number of productive collisions between interacting molecules. Previously was shown that the electron-ion interaction potential (EIIP) represents the physical property which determines the long-range properties of biological molecules. This molecular descriptor served as a base for development of the informational spectrum method (ISM), a virtual spectroscopy method for investigation of protein-protein interactions. In this paper, we proposed a new approach to treat small molecules as linear entities, allowing study of the small molecule - protein interaction by ISM. We analyzed here 21 sets of KEGG drug-protein interactions and showed that this new approach allows an efficient discrimination between biologically active and inactive ligands, and consistence with AA regions of their binding site on the target protein.
End-to-End Reverse Screening Identifies Protein Targets of Small Molecules Using HelixFold3
PaddleHelix Team(PaddleHelix团队);Baidu Inc.(百度公司);School of Software Engineering(软件工程学院);Huazhong University of Science and Technology(华中科技大学);School of Pharmacy, Tongji Medical College(药学院)
A small PAM optimises target recognition in the CRISPR-Cas immune system
CRISPR-Cas是一种适应性免疫机制,已被用于各种基因工程应用:Cas9蛋白识别2- 5 nt DNA基序,称为PAM,可编程crRNA结合靶DNA序列,然后切割。虽然脱靶活性是不希望的,但它的发生是因为交叉反应性在该机制所基于的免疫系统中是有益的。在这里,一个随机模型的目标识别反应的推导来研究的特异性先天免疫机制的细菌。在自身和噬菌体DNA上测试了具有识别不同长度PAM的Cas9蛋白的CRISPR系统。该模型显示与PAM结合相关的能量影响错配耐受性、切割概率和切割时间。小PAM允许CRISPR平衡捕获突变体,避免自我靶向,并快速与严重不匹配的序列分离。此外,结果揭示了对PAM和称为种子的PAM近端区域中的错配的较低耐受性,如实验中所见。这项工作说明了Cas9蛋白在决定DNA切割特异性方面的作用,这有助于防止生物技术应用中的脱靶活性。
Target Specific De Novo Design of Drug Candidate Molecules with Graph Transformer-based Generative Adversarial Networks
Biological Data Science Lab, Dept. of Computer Engineering, Hacettepe University(哈切塔佩大学计算机工程系生物数据科学实验室);Dept. of Computer Engineering, Hacettepe University(哈切塔佩大学计算机工程系);Dept. of Chemistry, Middle East Technical University(中东技术大学化学系);Dept. of Physics, Middle East Technical University(中东技术大学物理系);Dept. Of Artificial Intelligence Engineering, Bahcesehir University(巴切塞希尔大学人工智能工程系);Cancer Systems Biology Lab, Graduate School of Informatics, Middle East Technical University(中东技术大学信息研究生院癌症系统生物学实验室);Dept. of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University(加齐大学药学系药剂化学系);Laboratory of Molecular Modeling, Evias Pharmaceutical R&D Ltd.(Evias制药研发有限公司分子建模实验室);Dept. of Electrical and Electronics Engineering, İskenderun Technical University(伊斯肯德伦技术大学电子与电气工程系);Institute for Computational Biomedicine, Heidelberg University(海德堡大学计算生物医学研究所);Dept. of Bioinformatics, Graduate School of Health Sciences, Hacettepe University(哈切塔佩大学健康科学研究生院生物信息学系)
Molecule AI(分子人工智能公司);Manning College of Information and Computer Sciences, University of Massachusetts Amherst(马萨诸塞大学阿默斯特分校曼宁信息与计算机科学学院);Happening Technology Ltd(Happening科技有限公司);Indian Institute of Technology Delhi(印度理工学院德里分校)
Multi-objective generative AI for designing novel brain-targeting small molecules
Harvard University(哈佛大学);Hugh Kaul Precision Medicine Institute(休·考尔精准医学研究所);Heersink School of Medicine(赫辛克医学院);University of Alabama at Birmingham(阿拉巴马大学伯明翰分校);Harvard John A. Paulson School of Engineering and Applied Sciences(哈佛大学约翰·A·保尔森工程与应用科学学院)
AlphaFold Accelerates Artificial Intelligence Powered Drug Discovery: Efficient Discovery of a Novel Cyclin-dependent Kinase 20 (CDK20) Small Molecule Inhibitor
Insilico Medicine Shanghai Ltd(英矽智能上海有限公司);Insilico Medicine Kong Kong Ltd(英矽智能香港有限公司)